Sarepta and Genethon Collaborate on Gene Therapy Research for Duchenne – Rare Disease Report
|
Sarepta and Genethon Collaborate on Gene Therapy Research for Duchenne
Rare Disease Report Unlike Sarepta's current pipeline that is focused on specific dystrophin gene mutations, Genethon's micro-dystrophin gene therapy approach can target most patients with DMD, and the company has demonstrated proof-of-concept via robust gene expression … |
